Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201400
Title: | Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting. |
Author: | Greenberg, Lauren Ryom, Lene Neesgaard, Bastian Miró Meda, José M. Dahlerup Rasmussen, Line Zangerle, Robert Grabmeier-Pfistershammer, Katharina Günthard, Huldrych F.. Kusejko, Katharina Smith, Colette Mussini, Cristina Menozzi, Marianna Wit, Ferdinand Van Der Valk, Marc D'Arminio Monforte, Antonella De Wit, Stéphane Necsoi, Coca Pelchen-Matthews, Annegret Lundgren, Jens Peters, Lars Castagna, Antonella Muccini, Camilla Vehreschild, Jörg Janne Pradier, Christian Bruguera Riera, Andreu Sönnerborg, Anders Petoumenos, Kathy Garges, Harmony Rogatto, Felipe Dedes, Nikos Bansi-Matharu, Loveleen Mocroft, Amanda RESPOND Study Group |
Keywords: | Persones seropositives Antiretrovirals Càncer Inhibidors de la integrasa HIV-positive persons Antiretroviral agents Cancer Integrase inhibitors |
Issue Date: | 19-Jan-2022 |
Publisher: | Oxford University Press |
Abstract: | Background: Limited data exist examining the association between incident cancer and cumulative integrase inhibitor (INSTI) exposure. Methods: Participants were followed from baseline (latest of local cohort enrollment or January 1, 2012) until the earliest of first cancer, final follow-up, or December 31, 2019. Negative binomial regression was used to assess associations between cancer incidence and time-updated cumulative INSTI exposure, lagged by 6 months. Results: Of 29 340 individuals, 74% were male, 24% were antiretroviral treatment (ART)-naive, and median baseline age was 44 years (interquartile range [IQR], 36-51). Overall, 13 950 (48%) individuals started an INSTI during follow-up. During 160 657 person-years of follow-up ([PYFU] median 6.2; IQR, 3.9-7.5), there were 1078 cancers (incidence rate [IR] 6.7/1000 PYFU; 95% confidence interval [CI], 6.3-7.1). The commonest cancers were non-Hodgkin lymphoma (n = 113), lung cancer (112), Kaposi's sarcoma (106), and anal cancer (103). After adjusting for potential confounders, there was no association between cancer risk and INSTI exposure (≤6 months vs no exposure IR ratio: 1.15 [95% CI, 0.89-1.49], >6-12 months; 0.97 [95% CI, 0.71-1.32], >12-24 months; 0.84 [95% CI, 0.64-1.11], >24-36 months; 1.10 [95% CI, 0.82-1.47], >36 months; 0.90 [95% CI, 0.65-1.26] [P = .60]). In ART-naive participants, cancer incidence decreased with increasing INSTI exposure, mainly driven by a decreasing incidence of acquired immune deficiency syndrome cancers; however, there was no association between INSTI exposure and cancer for those ART-experienced (interaction P < .0001). Conclusions: Cancer incidence in each INSTI exposure group was similar, despite relatively wide CIs, providing reassuring early findings that increasing INSTI exposure is unlikely to be associated with an increased cancer risk, although longer follow-up is needed to confirm this finding. |
Note: | Reproducció del document publicat a: https://doi.org/10.1093/ofid/ofac029 |
It is part of: | Open Forum Infectious Diseases, 2022, vol. 9, num. 3, p. ofac029 |
URI: | http://hdl.handle.net/2445/201400 |
Related resource: | https://doi.org/10.1093/ofid/ofac029 |
ISSN: | 2328-8957 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
729587.pdf | 417.09 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License